Clinical trial · Interventional
High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
A Phase I Study On The Feasibility Of High Dose Three Dimensional Conformal Radiotherapy In Patients With Inoperable And Locally Advanced Non Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): low accrual
Summary
Brief summary (as posted)
RATIONALE: Using computer systems that create a 3-dimensional picture of the tumor to plan treatment may enable doctors to provide more effective radiation therapy that will cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of high-dose 3-dimensional conformal radiation therapy in treating patients with inoperable stage I, stage II, or stage IIIA non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Maximum tolerated dose as measured by NCI-CTC v2.0 during treatment and up to 6 months after completion of radiotherapy
Secondary outcomes (2)
- measure
- Late toxicity measured every 2 months in year 1, then every 3 months in year 2, and then every 6 months thereafter
- measure
- Disease progression measured every 2 months in year 1, then every 3 months in year 2, and then every 6 months thereafter
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed non-small cell lung cancer
* Medically inoperable stage I or II disease
* Stage III disease eligible provided the following are true:
* No supraclavicular node involvement
* No peripherally located lower lobe tumor AND contralateral upper mediastinal node involvement
* No distant metastasis
* No malignant pleural or pericardial effusion
PATIENT CHARACTERISTICS:
Age
* Not specified
Performance status
* WHO 0-2
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Cardiovascular
* No prior myocardial infarction
* No prior complete bundle branch block
* No other prior cardiovascular disease resulting in New York Heart Association class III or IV heart disease
* No clinically significant cardiac arrhythmias
* No congestive heart failure
Pulmonary
* FEV\_1 at least 1.2 L OR
* DLCO at least 60%
Other
* No other prior or concurrent malignancy except cured basal cell skin cancer or carcinoma in situ of the cervix
* No intractable or uncontrolled infection
* No psychological, familial, social, or geographical condition that would preclude study compliance and follow-up
* Able to tolerate a course of radiotherapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* At least 3 weeks since prior chemotherapy
* No prior anthracyclines
* No concurrent chemotherapy
Endocrine therapy
* Not specified
Radiotherapy
* No prior radiotherapy to the chest area
Surgery
* No prior therapeutic surgery to the chest area
Other
* No other prior therapy to the chest areaReferences
Publications (0)
Data not yet available